1Analysis Group, Inc., Boston, MA 02199, USA.
2Analysis Group, Inc., New York, NY, USA.
3Bristol-Myers Squibb, Princeton, NJ, USA.
Efficacy and safety comparison of daclatasvir/asunaprevir (DCV + ASV) versus peginterferon-α/ribavirin (A/R) alone or combined with telaprevir, boceprevir, simeprevir or sofosbuvir in chronic genotype 1b hepatitis C virus infection.
Network meta-analysis (NMA) and matching-adjusted indirect comparisons (MAICs).
Among treatment-naive patients, DCV + ASV demonstrated higher sustained virologic response (SVR) rates than telaprevir + A/R, boceprevir + A/R and A/R in NMA and MAICs and simeprevir + A/R in NMA. DCV + ASV among treatment-experienced patients had higher SVR rates than telaprevir + A/R, boceprevir + A/R, simeprevir + A/R and A/R in MAICs. DCV + ASV had lower adverse events rates than comparators.
DCV + ASV demonstrated superior efficacy and safety compared with A/R-based regimens.